famotidine has been researched along with Sclerosis, Systemic in 2 studies
Famotidine: A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Horikoshi, T | 2 |
| Matsuzaki, T | 2 |
| Sekiguchi, T | 2 |
| Kusano, M | 1 |
2 trials available for famotidine and Sclerosis, Systemic
| Article | Year |
|---|---|
Effect of H2-receptor antagonists cimetidine and famotidine on interdigestive gastric motor activity and lower esophageal sphincter pressure in progressive systemic sclerosis.
Topics: Cimetidine; Esophagogastric Junction; Famotidine; Female; Gastrointestinal Motility; Humans; Injecti | 1994 |
Effects of famotidine on upper gastrointestinal motility in patients with progressive systemic sclerosis.
Topics: Adult; Bicarbonates; Chi-Square Distribution; Famotidine; Female; Gastrins; Gastrointestinal Motilit | 1991 |